Compare OUST & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OUST | COLL |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | N/A | 2015 |
| Metric | OUST | COLL |
|---|---|---|
| Price | $24.98 | $45.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $34.80 | ★ $51.17 |
| AVG Volume (30 Days) | ★ 1.9M | 493.0K |
| Earning Date | 11-04-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.63 |
| Revenue | $137,298,000.00 | ★ $757,067,000.00 |
| Revenue This Year | $35.72 | $26.17 |
| Revenue Next Year | $35.65 | $3.65 |
| P/E Ratio | ★ N/A | $27.99 |
| Revenue Growth | ★ 30.20 | 26.34 |
| 52 Week Low | $6.34 | $23.23 |
| 52 Week High | $41.65 | $50.79 |
| Indicator | OUST | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 48.27 | 45.08 |
| Support Level | $23.53 | $44.43 |
| Resistance Level | $28.08 | $48.29 |
| Average True Range (ATR) | 1.95 | 2.08 |
| MACD | -0.05 | -0.20 |
| Stochastic Oscillator | 17.92 | 25.32 |
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.